Cholinesterase inhibitors for Parkinson's disease dementia (Q24244668)

Parkinson's disease dementia

Europe PubMed Central

title

Cholinesterase inhibitors for Parkinson's disease dementia (English)

0 references

1 reference

0 references

1 reference

Ian Maidment

1

0 references

Chris Fox

series ordinal

2

0 references

Malaz Boustani

series ordinal

3

0 references

publication date

25 January 2006

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Rivastigmine (Exelon) for dementia in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Risk of dementia in Parkinson's disease: a community-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Dementia with Lewy bodies: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Cognitive deficits in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

The effect of different diagnostic criteria on the prevalence of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Responses to donepezil in Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Treatment interventions for Parkinson's disease: an evidence based assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Cholinergic dysfunction in diseases with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Worldwide occurrence of Parkinson's disease: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

The cognitive drug research computerized assessment system for demented patients: A validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

7 January 2021

inferred from DOI database lookup

Cholinesterase inhibition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

7 January 2021

inferred from DOI database lookup

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004747.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD004747.PUB2

0 references

Fatcat ID

release_zo7l7q3tyvawdiaggcoccv2dv4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zo7l7q3tyvawdiaggcoccv2dv4

24 November 2022